
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is a rapidly growing company with a portfolio of innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of a patient's anatomy. With a strong focus on leveraging the body's natural healing response and minimizing long-term exposure to permanent synthetic materials, TELA Bio is well-positioned to succeed in the hernia repair and abdominal wall reconstruction market. While there are potential risks associated with government regulation and pending litigation, TELA Bio's track record of gaining regulatory approvals and its dedication to enhancing patient outcomes make it a promising investment.
Bears say
TELA Bio is focused on providing soft-tissue reconstruction solutions, but negative analyst sentiment stems from concerns about execution and conservative guidance. Their sales team reorganization and new hires give some hope for improvement in the second half of the year, but the company still has a lot of work to do. The lowered sales outlook and continued losses also contribute to a negative outlook, as does the concentrated product portfolio and reliance on reimbursement rates.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares